| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d220c6d8311d6252b12b5d9626add5f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 |
| filingDate |
2013-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae705250d68ad99fdbc2124a7b9d797a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ac289d2e14728b13cae6ef717645adb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159733c54b4c02d7ab8cc6bed6e0d0a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca44a763550ba47ec74029709789940
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b80a958329d92c481c4c6fd2b400b3f5 |
| publicationDate |
2015-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9145411-B2 |
| titleOfInvention |
Substituted amino-pyrimidine derivatives |
| abstract |
The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer. |
| priorityDate |
2012-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |